{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T04:59:20Z","timestamp":1789707560486,"version":"4.0.1"},"reference-count":31,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,5,16]],"date-time":"2025-05-16T00:00:00Z","timestamp":1747353600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>PCOS is a prevalent endocrine disorder characterized by metabolic dysfunctions, including insulin resistance and hyperandrogenism. Cryptotanshinone, a bioactive compound, has shown promise in addressing reproductive abnormalities. However, its therapeutic potential for the management of PCOS has not been sufficiently investigated.<\/jats:p><\/jats:sec><jats:sec><jats:title>Purpose<\/jats:title><jats:p>The aim of this study is to systematically evaluate the therapeutic efficacy of cryptotanshinone in the treatment of PCOS.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A comprehensive systematic search was performed across multiple databases, including CNKI, Wanfang Data, VIP, PubMed, and Web of Science, covering studies from their inception through December 2024. The methodological quality of the included studies was assessed using SYRCLE\u2019s Risk of Bias tool. Data synthesis and statistical analysis were conducted using RevMan 5.3 and Stata 17 software.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Seven studies met the inclusion criteria for meta-analysis. Treatment with cryptotanshinone significantly improved several PCOS-related parameters in animal models, as compared to the control group. Notable improvements included reductions in body weight (<jats:italic>P<\/jats:italic> &amp;lt; 0.00001), ovarian weight (<jats:italic>P<\/jats:italic> = 0.005), and ovaries quotiety (<jats:italic>P<\/jats:italic> = 0.0006). Additionally, cryptotanshinone treatment led to significant modulation of serum levels f T (<jats:italic>P<\/jats:italic> = 0.001), A2 (<jats:italic>P<\/jats:italic> = 0.02), LH (<jats:italic>P<\/jats:italic> = 0.0002), LH\/FSH ratio (<jats:italic>P<\/jats:italic> = 0.001), estradiol (<jats:italic>P<\/jats:italic> = 0.005), and SHBG (<jats:italic>P<\/jats:italic> = 0.0003). The underlying mechanism may involve the downregulation of CYP17 and AR mRNA and protein expression.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>This meta-analysis provides robust evidence supporting the therapeutic efficacy of cryptotanshinone in PCOS. Cryptotanshinone appears to restore both reproductive and metabolic functions, including the regulation of body weight, ovarian morphology, hormone levels, and gene expression. Cryptotanshinone holds significant promise as a potential therapeutic agent for the management of PCOS.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fphar.2025.1561164","type":"journal-article","created":{"date-parts":[[2025,5,16]],"date-time":"2025-05-16T09:07:52Z","timestamp":1747386472000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":4,"title":["Effects of cryptotanshinone in treatment of polycystic ovary syndrome in rats: a systematic review and meta-analysis"],"prefix":"10.3389","volume":"16","author":[{"given":"Pingping","family":"Su","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xv","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruoqian","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chang","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,5,16]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"115921","DOI":"10.1016\/j.biopha.2023.115921","article-title":"Cryptotanshinone regulates gut microbiota and PI3K-AKT pathway in rats to alleviate CUMS induced depressive symptoms","volume":"169","author":"Bian","year":"2023","journal-title":"Biomed. Pharmacother."},{"key":"B2","doi-asserted-by":"publisher","first-page":"113261","DOI":"10.1016\/j.biopha.2022.113261","article-title":"Sex hormone binding globulin as a potential drug candidate for liver-related metabolic disorders treatment","volume":"153","author":"Bourebaba","year":"2022","journal-title":"Biomed. Pharmacother."},{"key":"B3","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1210\/endo-123-2-733","article-title":"Insulin-like growth factor I and insulin potentiate luteinizing hormone-induced androgen synthesis by rat ovarian thecal-interstitial cells","volume":"123","author":"Cara","year":"1988","journal-title":"Endocrinology"},{"key":"B4","doi-asserted-by":"publisher","first-page":"E717","DOI":"10.1152\/ajpendo.00263.2013","article-title":"Characterizing the neuroendocrine and ovarian defects of androgen receptor-knockout female mice","volume":"305","author":"Cheng","year":"2013","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"key":"B5","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1016\/j.jsbmb.2008.03.014","article-title":"Defects in insulin signaling pathways in ovarian steroidogenesis and other tissues in polycystic ovary syndrome (PCOS)","volume":"109","author":"Diamanti-Kandarakis","year":"2008","journal-title":"J. Steroid Biochem. Mol. Biol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1097\/MED.0b013e328353732f","article-title":"Evolving utility of sex hormone-binding globulin measurements in clinical medicine","volume":"19","author":"Hammond","year":"2012","journal-title":"Curr. Opin. Endocrinol. Diabetes Obes."},{"key":"B7","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1186\/1471-2288-14-43","article-title":"SYRCLE's risk of bias tool for animal studies","volume":"14","author":"Hooijmans","year":"2014","journal-title":"BMC Med. Res. Methodol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1016\/j.fertnstert.2014.05.012","article-title":"Cryptotanshinone reverses ovarian insulin resistance in mice through activation of insulin signaling and the regulation of glucose transporters and hormone synthesizing enzymes","volume":"102","author":"Huang","year":"2014","journal-title":"Fertil. Steril."},{"key":"B9","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/j.gene.2016.07.067","article-title":"Elevated expression of steroidogenesis pathway genes; CYP17, GATA6 and StAR in prenatally androgenized rats","volume":"593","author":"Jahromi","year":"2016","journal-title":"Gene"},{"key":"B10","doi-asserted-by":"publisher","first-page":"815968","DOI":"10.3389\/fendo.2022.815968","article-title":"Effects of androgen excess-related metabolic disturbances on granulosa cell function and follicular development","volume":"13","author":"Liao","year":"2022","journal-title":"Front. Endocrinol. (Lausanne)"},{"key":"B11","doi-asserted-by":"publisher","first-page":"117346","DOI":"10.1016\/j.jep.2023.117346","article-title":"Mechanism of cryptotanshinone to improve endocrine and metabolic functions in the endometrium of PCOS rats","volume":"319","author":"Liu","year":"2024","journal-title":"J. Ethnopharmacol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"1192370","DOI":"10.3389\/fphar.2023.1192370","article-title":"Cryptotanshinone affects HFL-1 cells proliferation by inhibiting cytokines secretion in RAW264.7 cells and ameliorates inflammation and fibrosis in newborn rats with hyperoxia induced lung injury","volume":"14","author":"Ma","year":"2023","journal-title":"Front. Pharmacol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1210\/er.2015-1104","article-title":"The pathogenesis of polycystic ovary syndrome (PCOS): the hypothesis of PCOS as functional ovarian hyperandrogenism revisited","volume":"37","author":"Rosenfield","year":"2016","journal-title":"Endocr. Rev."},{"key":"B14","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1093\/humrep\/deh098","article-title":"Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS)","volume":"19","year":"2004","journal-title":"Hum. Reprod."},{"key":"B15","doi-asserted-by":"publisher","first-page":"100937","DOI":"10.1016\/j.molmet.2020.01.001","article-title":"Metabolic dysfunction in polycystic ovary syndrome: pathogenic role of androgen excess and potential therapeutic strategies","volume":"35","author":"Sanchez-Garrido","year":"2020","journal-title":"Mol. Metab."},{"key":"B16","doi-asserted-by":"publisher","first-page":"3347","DOI":"10.1002\/cphy.c210025","article-title":"Polycystic ovary syndrome and the neuroendocrine consequences of androgen excess","volume":"12","author":"Silva","year":"2022","journal-title":"Compr. Physiol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/s13048-025-01621-6","article-title":"Physiopathology of polycystic ovary syndrome in endocrinology, metabolism and inflammation","volume":"18","author":"Su","year":"2025","journal-title":"J. Ovarian Res."},{"key":"B18","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1159\/000049972","article-title":"Insulin resistance in nonobese patients with polycystic ovary syndrome","volume":"55","author":"Toprak","year":"2001","journal-title":"Horm. Res."},{"key":"B19","doi-asserted-by":"publisher","first-page":"R23","DOI":"10.1530\/JOE-19-0096","article-title":"Androgens and ovarian function: translation from basic discovery research to clinical impact","volume":"242","author":"Walters","year":"2019","journal-title":"J. Endocrinol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"1273542","DOI":"10.3389\/fendo.2023.1273542","article-title":"Androgen excess: a hallmark of polycystic ovary syndrome","volume":"14","author":"Wang","year":"2023","journal-title":"Front. Endocrinol. (Lausanne)"},{"key":"B21","doi-asserted-by":"publisher","first-page":"3490","DOI":"10.7620\/zgfybj.j.issn.1001-4411.2015.20.60","article-title":"The effect of salvianolic acid on glucose and lipid metabolism and sex hormones in polycystic ovary syndrome rats","volume":"30","author":"Wang","year":"2015","journal-title":"Chin. J. Maternal Child Health"},{"key":"B22","doi-asserted-by":"publisher","first-page":"115956","DOI":"10.1016\/j.biopha.2023.115956","article-title":"Cryptotanshinone suppresses ovarian cancer via simultaneous inhibition of glycolysis and oxidative phosphorylation","volume":"170","author":"Wang","year":"2024","journal-title":"Biomed. Pharmacother."},{"key":"B23","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.3390\/molecules26051460","article-title":"Cryptotanshinone ameliorates doxorubicin-induced cardiotoxicity by targeting Akt-GSK-3\u03b2-mPTP pathway in vitro","volume":"26","author":"Wang","year":"2021","journal-title":"Molecules"},{"key":"B24","doi-asserted-by":"publisher","first-page":"175434","DOI":"10.1016\/j.ejphar.2022.175434","article-title":"Cryptotanshinone modulates proliferation, apoptosis, and fibrosis through inhibiting AR and EGFR\/STAT3 axis to ameliorate benign prostatic hyperplasia progression","volume":"938","author":"Wei","year":"2023","journal-title":"Eur. J. Pharmacol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"104633","DOI":"10.1016\/j.fitote.2020.104633","article-title":"Cryptotanshinone: a review of its pharmacology activities and molecular mechanisms","volume":"145","author":"Wu","year":"2020","journal-title":"Fitoterapia"},{"key":"B26","first-page":"2447","article-title":"Cryptotanshinone reverses reproductive disturbances in rats with dehydroepiandrosterone-induced polycystic ovary syndrome","volume":"9","author":"Xia","year":"2017","journal-title":"Am. J. Transl. Res."},{"key":"B27","doi-asserted-by":"publisher","first-page":"R869","DOI":"10.1152\/ajpregu.00334.2010","article-title":"Cryptotanshinone reverses reproductive and metabolic disturbances in prenatally androgenized rats via regulation of ovarian signaling mechanisms and androgen synthesis","volume":"300","author":"Yang","year":"2011","journal-title":"Am. J. Physiol. Regul. Integr. Comp. Physiol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"3851","DOI":"10.3892\/mmr.2020.11469","article-title":"Cryptotanshinone alleviates polycystic ovary syndrome in rats by regulating the HMGB1\/TLR4\/NF-\u03baB signaling pathway","volume":"22","author":"Yang","year":"2020","journal-title":"Mol. Med. Rep."},{"key":"B29","first-page":"1699","article-title":"Study of cryptotanshinone on improving hyperandrogenism of polycystic ovary syndrome via down-regulating the expression of gene CYP17 and AR","volume":"29","author":"Yu","year":"","journal-title":"Chin. J. Traditional Chin. Med."},{"key":"B30","doi-asserted-by":"publisher","first-page":"670743","DOI":"10.1155\/2014\/670743","article-title":"Cryptotanshinone reverses reproductive and metabolic disturbances in PCOS model rats via regulating the expression of CYP17 and AR","volume":"2014","author":"Yu","year":"","journal-title":"Evid. Based Complement. Altern. Med."},{"key":"B31","doi-asserted-by":"publisher","first-page":"2735","DOI":"10.1210\/endo.141.8.7595","article-title":"Interactive stimulation by luteinizing hormone and insulin of the steroidogenic acute regulatory (StAR) protein and 17alpha-hydroxylase\/17,20-lyase (CYP17) genes in porcine theca cells","volume":"141","author":"Zhang","year":"2000","journal-title":"Endocrinology"}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1561164\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,16]],"date-time":"2025-05-16T09:07:54Z","timestamp":1747386474000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1561164\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,16]]},"references-count":31,"alternative-id":["10.3389\/fphar.2025.1561164"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2025.1561164","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,16]]},"article-number":"1561164"}}